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Very early Guillain-Barré syndromea b s t r a c t
Objectives: Using recent optimized electrodiagnostic criteria sets, we primarily aimed at verifying the
accuracy of the initial electrophysiological test in very early Guillain-Barré syndrome (VEGBS), 4 days
of onset, compared with the results of serial electrophysiology. Our secondary objective was to correlate
early electrophysiological results with sonographic nerve changes.
Methods: This is a retrospective study based on consecutive VEGBS patients admitted to the hospital.
Each patient had serial nerve conduction studies (NCS) in at least 4 nerves. Initial NCS were done within
4 days after onset, and serial ones from the second week onwards. Electrophysiological recordings of each
case were re-evaluated, GBS subtype being established accordingly. Nerve ultrasonography was almost
always performed within 2 weeks after onset.
Results: Fifteen adult VEGBS patients were identified with a mean age of 57.8 years. At first NCS, VEGBS
sub-typing was only possible in 3 (20%) cases that showed an axonal pattern, the remaining patterns
being mixed (combining axonal and demyelinating features) in 6 (40%), equivocal in 5 (33.3%), and nor-
mal in 1 (6.7%). Upon serial NCS, 7 (46.7%) cases were categorized as acute demyelinating polyneuropa-
thy, 7 (46.7%) as axonal GBS, and 1 (6.6%) as unclassified syndrome. Antiganglioside reactivity was
detected in 5 out of the 7 axonal cases. Nerve US showed that lesions mainly involved the ventral rami
of scanned cervical nerves.
Conclusions: Serial electrophysiological evaluation is necessary for accurate VEGBS subtype classification.
Ultrasonography helps delineate the topography of nerve changes.
Significance: We provide new VEGBS pathophysiological insights into nerve conduction alterations
within the first 4 days of the clinical course.
 2019 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Guillain-Barré syndrome (GBS) is an acute-onset, immune
mediated disorder of the peripheral nervous system, which
includes at least three disease patterns: acute inflammatory
demyelinating polyneuropathy (AIDP), acute motor axonal and
motor-sensory axonal neuropathy (AMAN and AMSAN) and
Miller-Fisher syndrome (MFS) (Griffin et al., 1996; van den Berg
et al., 2014). Furthermore, GBS andMFS are sub-classified into clas-sic and localized forms (Wakerley et al., 2014). AMAN/AMSAN and
MFS are associated with anti-ganglioside reactivity.
Nerve conduction studies (NCS) play an important role in GBS
diagnosis and subtype classification (Hadden et al., 1998;
Rajabally et al., 2015; Uncini and Kuwabara, 2018). It is debated
whether the GBS subtypes can be diagnosed by a single electro-
physiological study; given that GBS pathophysiology is dynamic,
serial studies seem to allow a more accurate diagnosis of subtypes
(Uncini et al., 2017). The accuracy of electrodiagnostic GBS sub-
typing has been optimized by adding, to existing criteria sets, dura-
tion of motor responses and reversible conduction failure (RCF) in
motor and sensory nerves upon serial evaluation (Uncini and
Kuwabara, 2018). In early GBS stages, arbitrarily encompassing
patients who underwent nerve conduction studies within 7 or
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malities that are not specific of primary demyelinating neuropathy
(Gordon and Wilbourn, 2001; Vucic et al., 2004; Chanson et al.,
2014). Reports focusing on the very early stages of GBS (VEGBS),
4 days after onset, indicate that 67% of electrodiagnostic studies
are classified as equivocal (Albertí et al., 2011). To the best of our
knowledge, there are no previous studies for establishing the diag-
nostic accuracy of optimized electrophysiology in VEGBS.
Nerve ultrasonography (US) has emerged as promising tech-
nique in the diagnosis of peripheral nervous system disorders
(Gallardo et al., 2015b). In VEGBS, US may show extensive enlarge-
ment of cross-sectional areas (CSA) in all nerves except of ulnar
and sural nerves (Grimm et al., 2014, 2016). In early GBS we have
reported that main US changes rely on ventral rami of C5-C7
nerves, consisting of significant increase of their CSA and blurred
boundaries (Gallardo et al., 2015a). Such imaging findings are in
good correlation with autopsy features in early stages of the dis-
ease showing that endoneurial inflammatory oedema is the out-
standing lesion predominating in proximal nerve trunks
(Gallardo et al., 2015a; Berciano et al., 2017).
Using Uncini’s optimized electrodiagnostic criteria of GBS sub-
types (Uncini et al., 2017), our primary objective was to analyse
the diagnostic accuracy at first electrophysiological test in VEGBS
patients compared with the results of serial electrophysiological
evaluation. Our secondary objective was to correlate early electro-
physiological features with topographic US nerve changes.2. Methods
2.1. Patients
This is a retrospective study based on consecutive GBS patients
attended at the University Hospital ‘‘Marqués de Valdecilla”,
between 2011 and 2018, whose initial electrophysiological evalua-
tion was carried out between days 1 and 4 of clinical onset. We
included patients with clinical data, laboratory tests and electro-
physiological results suggestive of classic GBS (Wakerley et al.,
2014; Asbury and Cornblath, 1990), with the exception of one
patient showing paraparetic axonal GBS (Berciano et al., 2016).
Clinical evaluation was done following the protocol reported in
two previous studies (Sedano et al., 1994, 2019). Clinical data
recorded during the acute phase of the illness included demogra-
phy, type of antecedent events and duration of the progressive
phase. Neurological manifestations at the nadir comprised motor
weakness distribution, involvement of cranial nerve, sensory loss,
presence of pain, and need of mechanically ventilated disease.
Eight cases of the series have been included in the IGOS study
(Doets et al., 2019), and 12 of them in a recent descriptive GBS sur-
vey carried out in our Institution (Sedano et al., 2019).
Standardized examination involved evaluation of muscle power
according to the Medical Research Council. Patients were graded
using GBS disability (GBSd) score, adapted from Winner and col-
leagues (Winer et al., 1988): 0 = healthy; 1 = minimal symptoms
or signs; 2 = able to walk without assistance, but unable to do man-
ual work; 3 = able to walk with assistance; 4 = chair/bed bound;
5 = mechanically ventilated; and 6 = dead. Leaving one deceased
patient aside, serial examination was systematically carried out
for a period ranging between 8 and 24 months after onset.
This investigation was approved by the Local Ethics Committee.2.2. Electrophysiological studies
Electromyography and NCS were performed using standard
techniques as reported elsewhere (Berciano et al., 2000). For the
current study, electrophysiological recordings were blinded re-evaluated by two of us (PO and JB), classification being done
according to optimized GBS criteria sets (Uncini et al., 2017) (Sup-
plementary material, Table S1).
At first electrodiagnostic evaluation (days 1–4), NCS were per-
formed in an ipsilateral upper extremity and lower extremity;
motor NCS was routinely estimated in median, ulnar, tibial and
peroneal nerves, and sensory NCS in median, ulnar, sural and
superficial peroneal nerves. Motor conduction parameters ana-
lyzed were as follows: motor conduction velocity (MCV), distal
motor latency (DML), compound muscle action potential ampli-
tude (CMAP; from baseline to negative peak), CMAP duration (from
first negative defection to return to baseline of the last negative
deflection), minimal F-wave latency, proximal CMAP (pCMAP)/dis-
tal CMAP (dCMAP) amplitude ratio, and pCMAP/dCMAP duration
ratio. dCMAP duration and temporal dispersion of median, ulnar,
tibial and peroneal nerves were evaluated in accordance with
Clouston and colleagues’ criteria (Clouston et al., 1994). F-wave
latencies were measured with each motor NCS for which a CMAP
result was obtained. Sensory conduction parameters included
peak-to-peak amplitude of sensory nerve action potential (SNAP)
and sensory conduction velocity (SCV). Both in motor and sensory
nerves, potential RCF was evaluated on serial electrophysiological
studies.
Repeated electrophysiological studies, two or more times, were
done at variable intervals, but always from the second week
onwards.
2.3. Laboratory investigations
Routine laboratory analyses included cerebrospinal examina-
tion and antiganglioside reactivity testing, this not being available
in two cases. Serum samples, collected in the first few days of the
clinical course, were tested by the line-blot EUROLINE Antigan-
glioside Profiles (Euroimmun, Medizinische, Labordiagnostika,
AG) for IgG/IgM antibodies against GM1, GM2, GM3, GD1a, GD1b
and GQ1b.
2.4. Ultrasonographic study
US examination was performed as reported elsewhere (Gallardo
et al., 2015a) and within the first two weeks after onset with just
one exception. Bilaterally, we studied C5–C7 nerves, median nerve
and ulnar nerve (at upper arm and forearm), radial nerve (at ante-
cubital fossa), tibial nerve (at popliteal fossa and ankle), peroneal
nerve (at popliteal fossa) and sural nerve (at ankle).
2.5. Statistical analysis
Quantitative variables were described by means and standard
deviations and qualitative variables by percentages. Comparisons
between quantitative variables were performed with Student’s T
test. All statistical tests were performed using SPSS software (ver-
sion 20).3. Results
3.1. Clinical and laboratory findings
Clinical and laboratory features are summarized in Table 1. The
series comprises 15 patients presenting with classic GBS, namely
all of them exhibited ascending flaccid and areflexic weakness
leading to quadriparesis in 14, or paraparesis in 1. Around half
the patients showed sensory loss or nerve trunk pain, and a quarter
of total exhibited cranial nerve involvement. Ages at diagnosis ran-
ged between 18 and 80 years (mean 57.8). The male/female ratio
Table 1
Clinical features.




1 64 M Diarrhoea 1 4 3 2 GM1, GD1a AMSAN
2 59 F Diarrhoea 2 5 2 2 Negative AIDP
3 69 M Diarrhoea 1 5 5 4a GM1 AMSAN
4 24 F No 2 2 1 1 Not studied AIDP
5 80 F Diarrhoea 1 5 NAb NA GM1, GD1a AMSAN
6 18 F Diarrhoea 1 4 2 1 Negative Axonal GBSc
7 77 M URTI 1 5 0 0 Negative AIDP
8 43 M Diarrhoea 1 4 3 2 GM1 AMAN
9 42 F URTI 1 2 0 0 Negative AIDP
10 62 M Diarrhoea 1 2 2 2 Negative Unclassified
11 74 M URTI 1 4 0 0 Negative AIDP
12 74 M URTI 1 4 1 0 Not studied AIDP
13 65 M Diarrhoea 1 4 2 2d Negative Axonal GBS
14 58 M Diarrhoea 1 4 2 2e GM1 AMAN
15 58 M URTI 3 5 1f NA Negative AIDP
Abbreviations: F = female; GBSd = GBS disability (for definition of GBSd score, see text); M = male; NA = not applicable; URTI = upper respiratory tract infection
aFour further details, see Sedano et al (2019); bDied 5 months after onset; cFor further details, see Berciano et al (2016); d,eGBSd score 18 months after onset; fGBSd score
8 months after onset.
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4 weeks before symptomatic onset, which were diarrhoea in 9
(60%) and upper respiratory tract infection in 5 (33%). Neither stool
culture nor serology for Campylobacter jejuni was investigated.
Upon serial evaluation up to a maximum of 24 months after onset,
7 (46.7%) cases were categorized as AIDP, 7 (46.7%) as axonal GBS,
and 1 (6.6%) as unclassified GBS (Table 1 and Fig. 1).
The interval from onset to nadir was lower than 7 days in 12
(80%) cases, lower than 14 days in 2 (13%), and lower than 21 days
in the remaining 1 (7%). At nadir, GBSd score was 5 (mechanically
ventilated) in 5 (33%) cases, 4 in 7 (47%) cases, and 2 (20%) in the
remainder. Positive anti-ganglioside reactivity occurred in 5 out
of 7 patients with a final diagnosis of axonal GBS (Table 1); arbi-
trarily, the acronyms AMAN and AMSAN are used for cases with
such reactivity, whereas axonal GBS is used when it is lacking. At
admission and taking final GBS sub-typing into account, mean peak
GBSd scores were 4.28 ± 0.49 for axonal GBS and 3.85 ± 1.35 for
AIDP, the difference not being significant (p = 0.13). Contrariwise,Fig. 1. Flow chart of VEGBS patient ascertainment according to initial (4 days after
Supplementary material). The middle panel of boxes indicates that initially accurate GBS
mixed pattern (combining criteria of both axonal failure and demyelination) evolved
normalization. For all 3 axonal GBS patients, sub-typing did not change. The only VEGBS
electrodiagnosis, disease sub-typing was not possible in 1 (6.7%) case (No. 10).at final evaluations mean GBSd score in axonal GBS, 2.43 ± 1.5,
was significantly higher than that of AIDP, 0.67 ± 0.82 (p = 0.027).
There was one fatal patient (case 5 in Table 1) suffering from
severe AMSAN that required continuous assisted mechanical ven-
tilation; she died five months after the onset. Another severe
AMAN patient (case 3), evolving into an AMSAN pattern, was con-
fined to bed two years after onset (for further details of this case,
see reference 20).
3.2. Electrophysiological findings
Table S2 (Supplementary material) summarizes the observed
features at first electrophysiological studies performed between
days 1 and 4 after onset (mean, 2.3). Altogether, motor and sensory
NCS were performed in 59 and 57 nerves, respectively. Using Unci-
ni’s GBS criteria sets (Uncini et al., 2017), the most frequent
changes observed in decreasing order were as follows: abnormal
F waves in 28 nerves (47.5%), CMAP amplitude reduction in 27onset) and subsequent electrophysiological evaluations (dates listed in Table S2,
sub-typing was only possible in 3 (20%) cases categorized as axonal pattern. Initial
into either AIDP or AMSAN. Initial equivocal pattern resulted in AIDP, AMSAN or
patient showing initial normal NCS evolved into axonal GBS. Note that after serial
4 J. Berciano et al. / Clinical Neurophysiology Practice 5 (2020) 1–9(45.7%), SNAP amplitude reduction in 18 (31.6%), reduced pCMAP/
dCMAP amplitude ratio in 12 (20.3%), increase of CMAP duration in
12 (20.3%), DML prolongation in 8 (13.5%), SCV slowing in 6 (10.5%)
and MCV slowing in 1 (1.7%). It is worthy of note that abnormal
pCMAP/dCMAP amplitude ratios should be interpreted with cau-
tion when dCMAP is lower than 1 mV. Absent F waves occurred
in 20 nerves exhibiting severe attenuation of dCMAP, whereas
the remaining 8 showed delayed responses in the demyelinating
range (120% ULN) in presence of normal or slight dCMAP ampli-
tude reduction. In keeping with this data, the observed electro-
physiological patterns (Fig. 1) were mixed, combining axonal and
demyelinating features (Fig. 2), in 6 (40%) cases, equivocal in 5
(33.3%), axonal in 3 (20%), and normal in 1 (6.7%). Therefore,
though initial electrophysiology showed features pointing to a
peripheral nerve disorder in a high proportion of cases, early accu-
rate sub-typing was only possible for the 3 (20%) cases showing an
axonal pattern.
SNAP amplitude reduction or its absence was initially observed
in 6 median nerves and 6 ulnar nerves, whereas such feature
occurred in only 2 sural nerves (Table S2, Supplementary material).
As indicated in Table S2 (Supplementary material), on initial
assessments there were other mild nerve conduction alterations,
not conforming to Uncini’s electrodiagnostic criteria sets for GBS
(Uncini et al., 2017). These are MCV slowing in 13 (23%) nerves,
F-wave prolongation in 13 (23%), DML increase in 11 (18.6%),
SCV slowing in 11 (19.3%), dCMAP attenuation in 3 (5.3%), andFig. 2. Three serial NCS of median nerve and peroneal nerve in case 15, performed on
conduction values, Table S2, Supplementary material). On day 2, median nerve shows ma
dCMAP amplitude ratio <0.7, and pCMAP/dCMAP duration ratio >130%. There is minimal
increase of dCMAP amplitude (upper tracing, 3 mV), its duration declining from 7.6 m
amplitude and duration ratios remain abnormal. MCV velocity is normal (55.4 m/s). Note
features are comparable to the previous study. With regard to peroneal nerve, on day 2 t
DML is clearly prolonged, MCV is minimally slowed (see Table S2 for values). Note the
minimal variation of recordings in comparison with the previous study, excepting for an
day 28, the main variations are an evident increase of DML (first tracing, 9.9 ms; +18
electrophysiological pattern has evolved into AIDP. It is worth noting that despite pe
favourable, his GBSd score passing from 5 at admission to 1 eight months after onset. Ab
potential; DML = distal motor latency; EDB = extensor digitorum brevis; ER = extensor re
motor conduction velocity; pCMAP = proximal CMAP; ULN = upper limit of normal.SNAP amplitude reduction in 2 (3.5%). Taking together all this
information into account, F-wave alteration, occurring in 70.5%
out of explored nerves, was by far the commonest electrophysio-
logical feature.
One to 4 (median 2) serial NCS were performed from the second
week onwards (Table S2, Supplementary material). Final patient
categorization upon serial electrophysiological evaluation is sum-
marized in Fig. 1: i/ initial mixed pattern in six patients evolved
to either AIDP (Fig. 2) or AMSAN; ii/ five patients with initial equiv-
ocal pattern resulted in AIDP, AMSAN or normalisation; iii/ all
three patients with an initial axonal pattern remained under this
category, here divided into either AMAN (with ganglioside reactiv-
ity) or axonal GBS (without ganglioside reactivity); and iv/ the only
patient who exhibited normal initial electrodiagnosis evolved into
an axonal pattern.
Initially electromyography of tibialis anterior and abductor pol-
licis brevis revealed a variable decrease of recruitment pattern
with no spontaneous activity. On serial examination, active dener-
vation potentials were recorded in 6 cases (Nos. 2, 3, 6–8, and 14)
with primary or secondary axonal degeneration.3.3. Ultrasonographic study
US was carried out in 14 patients between days 2 and 22 (mean,
7.0) after onset; in case 1, it was not done. The results of nerve
ultrasonography are summarized in Table 2. Normative CSA valuesdays 2, 11 and 28 after onset (for clinical data see Table 1, and for initial nerve
rked amplitude reduction of dCMAP (upper tracing, 1 mV; normal, 4 mV), pCMAP/
alteration of DML and MCV, dCMAP duration being preserved. On day 11, note 300%
s to 6.5 ms; consequently, these changes are indicative of RCF. pCMAP/dCMAP
CMAP temporal dispersion in three bottom tracings. On day 28, electrophysiological
here is marked amplitude reduction of dCMAP that exhibits normal duration. While
presence of CMAP desynchronization in two bottom tracings. On day 11, there are
increase of dCMAP duration (8.7 ms), and decrease of MCV (30.5 m/s; 72% LLN). On
0% ULN) and further decrease of MCV (28.1 m/s; 67% LLN). In short, initial mixed
rsistent dCMAP amplitude reduction of lower-limb nerves, clinical evolution was
breviations: APB = abductor pollicis brevis; dCMAP = distal compound motor action
tinaculum; FH = fibular head; PF = popliteal fossa; LLN = lower limit of normal; MCV
Table 2
Ultrasonography CSA values of peripheral nerve trunks in cases 2 to 15 (similar numbering as in Table 1).
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12 17 7 6 9 5 6 6 6 12 23 21 12 12 6 8 NA NA
Mean 7.0 10.1a 8.8b 17.9c 15.4d 20.1e 17.5a 10.9f 12.2 g 7.4 7.0 8.4f 8.2 h 6.4 5.3 5.3 5.9 22.8 25.7 15.6 16.9 11.3 10.6 2.6 2.9
(SD) (5.3) (4.3) (3.6) (8.8) (4.6) (12.4) (5.6) (3.4) (4.2) (1.5) (1.4) (2.6) (2.6) (2.0) (1.3) (1.8) (2.4) (9.6) (9.1) (6.6) (6.6) (4.7) (4.0) (0.7) (1.1)
Abbreviations: AF = antecubital fossa; BB = blurred boundaries (ventral rami of C5-C7 nerves); CSA = cross sectional area; NA = not available; PF = popliteal fossa; R = right; L = left; UA = upper arm.
Underlined values are those over X + 2SD of normative values reported in the literature (Cartwright et al., 2008; Kerasnoudis et al., 2014; Gallardo et al., 2015a)
Statistical significance of enlarged mean CSA values of C5-C7 nerves compared with those reported by Gallardo et al., (2015a): (a) p < 0.004; (b) p < 0.01; (c) p < 0.002; (d) p < 0.0004; (e) p < 0.03.












Fig. 3. US of the ventral rami of the left fifth and sixth cervical nerves of case 12 with initial equivocal electrophysiological pattern evolving into AIDP (see Table 1 and Fig. 1);
sonograms were obtained on day 6 after onset. (A and B) Short-axis sonograms showing enlarged CSAs of both cervical nerves (dotted green tracings; for values see Table 2);
note that perineurial hyperechoic rims are not identified and that the edge between the nerve and the surrounding fat is not clear. (C) Sagittal sonograms showing blurred of
boundaries of both nerves (asterisks). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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C5–C7 nerves were taken from those reported in the literature
(Cartwright et al., 2008; Kerasnoudis et al., 2014; Gallardo et al.,
2015a). Figs. 3 and 4 illustrate the main sonographic finding that
relied on ventral rami of C5–C7 nerves, which consisted of a vari-
able combination of symmetric or asymmetric blurred boundaries
and significant increase of CSA (Table 2). Loss of the physiologic
hyperechoic perineurial rim was observed between 50% and
71.4% of individual scanned cervical nerves; CSA enlargement ran-
ged from 35.7% to 57.1%. Although, most enlarged spinal nerves
also exhibited blurred boundaries, there were examples showing
one of the two changes in isolation. C5–C7 sonographic findings
were similar in patients eventually categorized as AMAN/AMSAN
or AIDP. It is worth noting that just 2 cases (14.3%) showed entirely
normal C5-C7 nerve sonograms.
In more distant nerve trunks sonographic changes were scanty
and consisted of increased CSA, which at most involved 4 (28.6%)
left median nerves and 4 (28.6%) right ulnar nerves at upper-arm
level; increase of mean CSA was only significant for median and
ulnar nerves at upper-arm level (Table 2). At forearm level,
enlarged CSA was just observed in 2 (14.3%) right ulnar nerves
and 1 (7.1%) right median nerve; radial nerve was always normal.
In lower-limb nerves, enlarged CSA was observed at most in 2
(14.3%) left tibial nerves at ankle; sural nerve was always
preserved.4. Discussion
In the 8-year period of the current study, 15 VEGBS adult
patients were identified, upon whom serial electrophysiological
studies were available, the initial ones having always been per-
formed within the first four days of the clinical course. For the first
time, we used the optimized electrodiagnostic criteria recently
reported by Uncini and colleagues for subtype GBS classification
(Uncini et al., 2017). Furthermore and as soon as practicable, in
14 patients we performed nerve US in order to correlate early elec-
trophysiological features and topographic US nerve changes. The
series included 14 patients with classic GBS, and one patient with
paraparetic GBS (Wakerley et al., 2014; Berciano et al., 2016). We
have to admit that selection of VEGBS patients inevitably implies
that one is dealing with severe disease forms admitted promptly
to the hospital; in fact, 80% of cases showed severe peak GBSd
scores, 4 or 5, as opposed to 51.3% observed in our recent, unbiased
GBS survey (Sedano et al., 2019).4.1. Electrophysiological features
In our series, initial NCS indicate that accurate VEGBS sub-
typing was just possible for the 3 (20%) patients showing an axonal
pattern; intriguingly, this subtype did not change on serial evalua-
tion. In the remaining 12 (80%) cases, initial NCS revealed mixed
pattern (combining the criteria of both axonal dysfunction and
demyelination) in 6, equivocal pattern in 5 (not fulfilling any of
the AIDP or axonal GBS criteria) and normal pattern in 1. Upon
serial electrophysiological evaluation, GBS subtypes were set down
as follows: 7 AIDP, 7 axonal GBS and 1 unclassified (see Fig. 1)
There are just four previous clinical-electrophysiological studies
in VEGBS (Gordon and Wilbourn, 2001; Albertí et al., 2011;
Chanson and Echaniz-Laguna, 2014; Jin et al., 2018). Gordon and
Wilbourn (2001) carried out early electrodiagnostic studies in 31
cases GBS patients, in 8 of them within 4 days. Although absent
H reflex was observed in 7 (88%) cases, they stated that ‘‘Electrodi-
agnostic studies performed before the fifth day were likely to be
non-diagnostic”. Albertí et al. (2011) studied 18 VEGBS adult
patients with follow-up at 3 months being available in 14 of them.
While 15 (83%) cases showed abnormal motor conduction param-
eters, only 5 (27%) fulfilled their criteria for AIDP and 1 (6%) for the
axonal variant of GBS, namely 12 (67%) cases eventually were clas-
sified as equivocal. In the comprehensive early AIDP series
reported by Chanson and Echaniz-Laguna (2014), there was a sub-
group of 21 cases examined 4 days, whose electrodiagnostic reli-
ability was extremely variable, ranging between 19% using
Cornblath criteria (Cornblath, 1990) and 65% applying their own
proposed criteria. In a recent study, Jin et al. (2018) reported elec-
trophysiological features in 51 GBS patients classified into 3 sub-
groups according to the intervals of symptom onset and NCS,
namely 1–4 days (11 cases), 5–10 days (20 cases) and >10 days
(20 cases). One case of the very early subgroup showed normal
neurophysiological findings, while the remaining 10 patients dis-
played abnormal features; contrary to what might be expected
from our results, comparison of inter-subgroup percentages of
electrophysiological changes did not show significant differences.
Chanson and Echaniz-Laguna (2014) have tabulated in detail so
far reported VEGBS electrophysiological features (see their Table 1).
Although we adhered to GBS optimized electrodiagnosis (Uncini
et al., 2017), there is, to some degree, certain parallelism between
results in previous VEGBS series and those reported here, namely:
i/ abnormal F waves, 55–75% (here, 47.5%); ii/ dCMAP attenuation,
37–57% (55%); iii/ SNAP attenuation, 25–44% (31.6%); iv/ DML pro-
longation in the demyelinating range, 33–38% (13.5%); and v/ MCV
Fig. 4. US of the ventral rami of the sixth cervical nerves of case 13 with a final diagnosis of axonal GBS (see Table 1 and Fig. 1); sonograms were obtained on day 5 after onset.
(A) Short-axis sonogram showing marked CSA enlargement of the right C6 nerve (dotted green tracing; for values, see Table 2), its perineurial rim not being identified. (B) In
this sagittal sonogram the right C6 nerve (asterisks), note also disappearance of perineurial rim.(C) Short-axis sonogram of the left C6 nerve showing normal CSA (dotted
green tracing; for values, see Table 2) with preservation of the perineurial hyperechoic rim. (D) Sagittal sonogram of the left C6 nerve (asterisks) illustrating quite well
preservation of its perineurial hyperechoic rim. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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together optimized abnormal electrophysiological features and
mild nerve conduction changes, not conforming to Uncini’s GBS
electrodiagnostic criteria (Uncini et al., 2017), alteration of F waves
was the most frequent finding involving here 70.5% of examined
motor nerves.
4.2. Ultrasound features
The current nerve US study corroborates that main lesions rely
on ventral rami of C5–C7 nerves occurring equally in patientsfinally categorized as axonal GBS or AIDP (Gallardo et al., 2015a).
Spinal nerves are usually monofascicular with epi-perineural cov-
ering, which accounts for their sonographic appearance consisting
of hypoechoic oval structure surrounded by hyperechoic per-
ineurial rim (Haun et al., 2010). Autopsy studies in early AIDP have
demonstrated that initial lesion is inflammatory oedema predom-
inating in spinal roots and ventral rami of spinal nerves (Haymaker
and Kernohan, 1949; Krücke, 1955; Berciano et al., 2017). Intrigu-
ingly, such topography of lesions concurs with that originally
found in AMAN, literally reported as follows (McKhann et al.,
1993): ‘‘The most proximal site of fibre degeneration was in the
8 J. Berciano et al. / Clinical Neurophysiology Practice 5 (2020) 1–9proximal or mid-ventral roots; the proportion of degenerating
fibres increased distally toward the ventral root exit from the dura.
At this level, up to 80% of motor fibres were degenerating”. Accord-
ing to such pathological notions, our main sonographic findings
include a variable combination of significant CSA enlargement of
C5–C7 nerves and blurred boundaries. Furthermore, the observed
high prevalence of early F-wave alterations in our and other series
also point to pathological changes in proximal nerve trunks
(Berciano et al., 2017). Experimentally, blood-nerve interface is less
efficient in several important structures in the peripheral nervous
system, including from the spinal cord to the root-nerve junction
(spinal nerve), dorsal root ganglia and neuromuscular junctions
(Olsson, 1968; Kanda, 2013); hence these sites are believed to be
especially vulnerable to inflammatory neuropathies. In addition,
the pathogenic relevance of proximal nerve trunk lesions in AIDP
and AMAN has been demonstrated by means of lumbar root stim-
ulation (Kurt Incesu et al., 2013) and triple stimulation technique
(Sevy et al., 2018), respectively.
In more peripheral nerve trunks, our US study showed that sig-
nificant CSA enlargement occurs only in median and ulnar nerves
at upper-arm level. In a previous VEGBS sonographic investigation,
significant enlargement was found in all measured nerves, except
the sural nerve (Grimm et al., 2016). The obvious discrepancy calls
for new US studies.4.3. Pathophysiological considerations
Experimental autoimmune neuritis (EAN) has provided some
important information regarding the pathogenic mechanisms of
GBS (Soliven, 2012). We will focus on some of them to decipher
certain electrophysiological findings described here. In EAN medi-
ated by P2-reactive T-cell lines in Lewis rats, flaccid tail and weak-
ness of the hindlimbs start 3.5–4 days post-inoculation (pi),
whereas the first evidence of pathologic change, consisting of sev-
ere epi-perineurial and endoneurial inflammatory oedema in the
sciatic nerve, comes out 4 days pi, obvious demyelination and axo-
nal degeneration appearing between days 7 and 9 (Izumo et al.,
1985). In L5 root, at peak disease (day 6) the mean number of
demyelinated axons is 79/mm2 (0.7% of the total number), and of
degenerating axons is 121/mm2 (1.0% of the total) (Hadden et al.,
2002); certainly, such low percentage of nerve fibre degeneration
does not seem sufficient to explain maximal neurologic deficit
(complete limb paralysis). In nerves possessing epi-perineurium,
axonal damage appears at the height of the inflammatory process
(day 7 pi), when oedema and increase of endoneurial pressure
are maximal, which are believe to stretch the perineurium and
constrict the transperineurial microcirculation, compromising
nerve blood flow and producing the potential for ischemic nerve
injury (Powell et al., 1991; Powell and Myers, 1996). Such mecha-
nism has been illustrated in a clinico-patological study of a severe
AIDP patient (Berciano et al., 2000).
The notion that nerve inflammatory oedema might be patho-
genic in VEGBS, when neither full-blown demyelination nor
wallerian-like degeneration has entered into the scene, helps clar-
ify some of our initial electrophysiological findings, namely:
 Mixed pattern observed in 40% of our patients, which evolved
into either AIDP or AMSAN, is probably accounted for by
ischemic injury of distal peripheral nerve trunks causing
dysfunction of conducting myelinated fibres, axons, or both.
Given that such nerve segments are not amenable to sonogra-
phy and histological studies of terminal and pre-terminal
nerve segments are lacking, serial proximal-to-distal nerve
trunk histological studies in fatal VEGBS seem to be a pressing
need. In axonal VEGBS with normal electrophysiology, the presence
of sonographic changes in ventral rami of C5-C7 nerves point
to a proximal nerve conduction block as the mechanism of
paralysis.
 It is a well-established fact that in AMAN/AMSAN anti-
ganglioside antibodies bind to axolemma causing conduction
failure and eventually axonal degeneration (Rajabally et al.,
2015; Uncini et al., 2017; Uncini and Kuwabara, 2018). In our
axonal cases, US regularly showed changes in ventral rami of
C5-C7 nerves. Therefore, we propose that in very early AMAN
there may be a dual mechanism of muscle weakness: i/
ganglioside-mediated distal motor conduction block, not amen-
able to US visualization; and ii/ conduction block at ventral rami
of spinal nerves induced by inflammatory oedema.
 Characteristic of AMAN/AMSAN is dCMAP attenuation with nor-
mal duration. Here we report an AMSAN patient with wide-
spread amplitude reduction of dCMAPs accompanied by
reversible increase of their duration (see Table S2; Supplemen-
tary material). This phenomenon could be associated with early
but regressive inflammatory events of pre-terminal nerve
trunks causing ischemic dysfunction of motor conduction fibres.
 RCF is one of the hallmarks of AMAN. Here we describe this phe-
nomenon in an AIDP patient with no ganglioside reactivity (see
Fig. 2B). Again, its pathophysiology could be correlated with
early inflammatory oedema of distal nerve trunks.
5. Limitations
The present study has limitations including the retrospective
nature, the reduced number of patients collected from a single hos-
pital, the absence of scheduled dates for serial NCS, and no con-
comitance between initial NCS and nerve sonographic study. For
better pathogenic understanding we need large and prospective
electrophysiological and ultrasonographic studies in very early
stages of the disease, which should be done on a multinational,
multicenter basis.
6. Conclusion
In VEGBS serial electrophysiological evaluation is necessary for
accurate subtype classification. Nerve ultrasonography helps delin-
eate the topography of changes in early stages of the disease.
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